Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML
A Phase I Study to Evaluate the Safety and Efficacy of Allogeneic CAR-T Cells (CT0890B) in Patients With NKG2DL-Positive Relapsed/Refractory Acute Myeloid Leukemia
Peking University People's Hospital
27 participants
May 7, 2026
INTERVENTIONAL
Conditions
Summary
A Clinical Study to Investigate the Safety and Efficacy of CT0890B in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
Eligibility
Inclusion Criteria11
- Age 18-70 years (inclusive), male or female.
- Relapsed or refractory acute myeloid leukemia (R/R AML) diagnosed according to the 2022 World Health Organization classification or ELN criteria, with confirmed NKG2D ligand-positive disease.
- Bone marrow blasts ≥5% by morphology.
- Estimated life expectancy >12 weeks.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Adequate organ function without ongoing supportive care, defined as:
- Cardiac: left ventricular ejection fraction (LVEF) ≥50%;
- Hepatic: ALT and AST ≤2.5 × upper limit of normal (ULN), and total bilirubin ≤2 × ULN;
- Renal: creatinine clearance ≥30 mL/min (calculated using the Cockcroft-Gault formula);
- Coagulation: activated partial thromboplastin time (APTT) ≤1.5 × ULN and prothrombin time (PT) ≤1.5 × ULN.
- c) Renal: creatinine clearance ≥30 mL/min (calculated using the Cockcroft-Gault formula); d) Coagulation: activated partial thromboplastin time (APTT) ≤1.5 × ULN and prothrombin time (PT) ≤1.5 × ULN.
Exclusion Criteria13
- Participants were diagnosed with acute promyelocytic leukemia (APL), BCR-ABL positive leukemia (chronic myeloid leukemia in acute phase), central nervous system leukemia;
- Participants with a history of epilepsy or other central nervous system disease;
- Participants who have previously received autologous or allogeneic CAR-T therapy;
- Participants who have received autologous stem cell transplantation or allogeneic stem cell transplantation within 12 weeks
- Participants who have received prior immunotherapy targeting NKG2DL;
- Participant has clinically significant active GVHD or is receiving systemic corticosteroids for GVHD;
- Participant has any of the following at screening:
- Active, uncontrolled systemic infection or requiring intravenous anti-infective agents 2)Any of the following cardiac conditions, including:
- New York Heart Association Class III-IV heart failure;
- History of myocardial infarction, coronary artery bypass grafting, or unstable angina within 6 months prior to Qinglin;
- History of uncontrolled arrhythmia of significant clinical significance (as judged by the investigator), such as ventricular arrhythmia;
- History of severe nonischemic ardiomyopathy;
- Other cardiac disease that the investigatorbelieve could jeopardize the participant 's well-being or compromise participation in this clinical trial; 3) Active bleeding of clinical significance as judged by the investigator; 4)Requiring supplemental oxygen to maintain oxygen saturation> 92%; 5)Patients with severe chronic obstructive pulmonary disease (COPD) or other lung diseases that cannot tolerate CAR-T treatment as judged by the investigator;
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Conditioning regimen: Days -9 to -3: Venetoclax administered with a target dose of 200 mg/day. Days -5 to -4: Cytarabine administered at 500 mg/m²/day. Days -5 to -3: Cyclophosphamide at 300 mg/m²/day plus Fludarabine at 30 mg/m²/day. Day 0: Infusion of CT0890B CAR-T cells at one of four dose levels using an i3+3 Dose-Escalation Design: 1.5 × 10⁸ total cells, 3.0 × 10⁸ total cells, 4.5 × 10⁸ total cells, 6.0 × 10⁸ total cells
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07617285